ASX ANNOUNCEMENT

18 November 2026

Results of 2026 Annual Meeting of Stockholders

Saluda Medical, Inc. (**ASX:SLD**, "**Saluda**" or the "**Company**"), refers to the Annual Meeting of Stockholders held today. The results of the meeting are set out in the attached document in accordance with ASX Listing Rule 3.13.2. All resolutions were decided and passed by way of a poll.

ENDS

This announcement has been authorised for release by Saluda Medical's Disclosure Committee.

For more information, please contact:

Investors		**Media**
James Erickson	Sam Wells	Matt Wright
Chief Financial Officer	NWR Communications	NWR Communications
investors@saludamedical.com	+61 (0) 427 630 152	+61 (0) 451 896 420
	sam@nwrcommunications.com.au	matt@nwrcommunications.com.au

About Saluda Medical

Saluda Medical is a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel neuromodulation platform. The Company's closed-loop, dose-control platform senses and measures neural responses to stimulation and automatically adjusts therapy based on real-time neurophysiological feedback. The Company's first product, the Evoke® System, is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain, and is designed to treat chronic neuropathic pain by providing spinal cord stimulation (SCS) therapy that senses and measures neural activation to optimize therapy and reduce patient and clinician burden. 12-month results from the EVOKE study, the first and only prospective, multi-center, parallel-arm, double blind, randomized controlled pivotal study with a voluntary crossover arm in SCS, that demonstrated clinically superior pain relief to open-loop therapy, were published in The Lancet Neurology, 24-month results were published in JAMA Neurology, and 36-month data, that demonstrated sustained pain relief, were published in Regional Anesthesia and Pain Medicine. To learn more, including risks and important safety information, visit www.saludamedical.com/us/safety/.

Foreign Ownership Restriction

Saluda's CHESS Depositary Interests (CDIs) are issued in reliance on Regulation S under the U.S. Securities Act of 1933, as amended (the U.S. Securities Act), and a no-action letter issued by the staff of the U.S. Securities and Exchange Commission. Accordingly, the Company's CDIs have not been, and

will not be, registered under the U.S. Securities Act (except pursuant to an effective registration statement) or the securities laws of any state or other jurisdiction in the United States. The holders of Saluda's CDIs may not offer, sell, pledge, or otherwise transfer the CDIs into the United States or to, or for the account or benefit of, a "U.S. Person" (as defined in Rule 902(k) of Regulation S under the U.S. Securities Act) for a period of at least 12 months from the allotment date under the IPO, unless the resale of the CDIs is registered under the U.S. Securities Act or an exemption from registration is available.

Results of meeting

Name of entity

Saluda Medical, Inc

ABN/ACN/ARSN/ARBN

ARBN 691 140 360

Date of meeting

18 November 2026 AEDT (17 November 2026 U.S. Central Time)

Resolutions voted on at the meeting					If decided by poll					Proxies received			
Resolution		Result	Voting method	If s250U applies	Voted for		Voted against		Abstained	For	Against	Abstain	Discretion
No	Short description				Number	%	Number	%	Number	Number	Number	Number	Number
1	Election of Class I Director – Mr Robert Faulkner	Passed	Poll	N/A	15,179,460	99.96	0	0	6,210	15,179,460 (99.96%)	0	6,210 (0.04%)	-
2	Election of Class I Director – Dr Geoffrey Brooke M.B.B.S.	Passed	Poll	N/A	15,179,460	99.96	0	0	6,210	15,179,460 (99.96%)	0	6,210 (0.04%)	-
3	Approval of 10% Placement Facility	Passed	Poll	N/A	15,157,611	99.82	20,196	0.13	7,863	15,157,611 (99.82%)	20,196 (0.13%)	7,863 (0.05%)	-